Streetbeat News

Revenues

BTMD

Biote has revised its FY23 revenue forecast to $190M-$200M, which is lower than the previous estimate of $195.36M. The company attributes this to temporary inefficiencies from the realignment and expansion of sales geographies and evolving market dynamics. The company expects a slower growth pace in the second half of 2023.

Portfolio Pulse from Happy Mohamed

August 10, 2023 | 8:33 pm

EVLV

Evolv Technologies reported better-than-expected Q2 financial results and raised its FY23 revenue guidance above estimates, leading to a rise in its share prices.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 8:32 pm

BURU

Nuburu has reiterated its 2023 revenue outlook, expecting to generate over $3M.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 8:30 pm

YMAB

Y-mAbs Therapeutics has reiterated its FY23 revenue guidance in the range of $80M-$85M, which is in line with the estimated $82.79M.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 8:28 pm

IONQ

IonQ expects its Q3 revenue to be between $4.8M and $5.2M, compared to the estimated $4.94M.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 8:26 pm

IONQ

IonQ has projected its FY23 revenue to be between $18.9M and $19.3M, which is in line with the estimated $19.29M.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 8:25 pm

PGY

Pagaya Technologies has released its Q3 and FY23 outlook. The company expects Q3 revenue to be between $190M-$200M, lower than the estimated $207.83M. For FY23, the revenue is projected to be between $775M-$825M, which is in line with the estimated $805.37M. The company is also raising its outlook for Network Volume and Adjusted EBITDA.

Portfolio Pulse from Happy Mohamed

August 10, 2023 | 8:14 pm

MAXN

Maxeon Solar Technologies has revised its Q3 2023 revenue guidance to $280M-$320M, lower than the estimated $395.32M. The company also adjusted its FY23 revenue forecast to $1.25B-$1.35B, below the $1.51B estimate. The changes reflect a softening of residential demand and challenging market conditions expected to persist through Q4.

Portfolio Pulse from Happy Mohamed

August 10, 2023 | 8:12 pm

APYX

Apyx Medical Corporation has reaffirmed its revenue guidance for FY23, expecting to generate between $59M and $62M.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 8:11 pm

VLD

Velo3D has projected its FY23 revenue to be between $105M-$115M, which is lower than the estimated $121.64M. The company attributes this to delays in booking certain orders.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 8:08 pm